Annexon (NASDAQ:ANNX) Stock Rating Lowered by Wall Street Zen

Annexon (NASDAQ:ANNX) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

ANNX has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Annexon in a report on Monday, July 20th. Citigroup assumed coverage on shares of Annexon in a research report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Annexon in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Annexon has an average rating of “Hold” and an average price target of $15.33.

Annexon Stock Performance

ANNX stock opened at $5.29 on Friday. Annexon has a fifty-two week low of $2.03 and a fifty-two week high of $7.18. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -4.56 and a beta of 1.18. The business’s 50 day moving average price is $5.35 and its two-hundred day moving average price is $5.50.

Annexon (NASDAQ:ANNX) last released its earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). Sell-side analysts forecast that Annexon will post -1 earnings per share for the current year.

Insider Buying and Selling at Annexon

In related news, Director Muneer A. Satter acquired 613,497 shares of Annexon stock in a transaction that occurred on Thursday, May 28th. The stock was bought at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the transaction, the director directly owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ANNX. CIBC Bancorp USA Inc. purchased a new stake in shares of Annexon in the third quarter worth $31,000. Engineers Gate Manager LP bought a new position in shares of Annexon during the second quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after purchasing an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Annexon in the 4th quarter worth about $50,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Annexon in the 4th quarter worth about $52,000.

More Annexon News

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $14 price target, substantially above the stock’s recent trading level near $5.29. The firm continues to project a path to profitability, with estimated positive EPS of $0.03 in 2029 and $0.45 in 2030. HC Wainwright earnings estimates and rating
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, while WallStreetZen separately lowered its rating. The conflicting actions point to more cautious or mixed views among analysts rather than a clear change in the company’s fundamental outlook. Citizens JMP rating update WallStreetZen rating update
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030, including Q3 2026 EPS to a $0.27 loss from a $0.22 loss, FY2026 to a $0.99 loss from $0.90, and FY2029 earnings to $0.03 from $0.13. The firm also cut its FY2030 estimate to $0.45 from $0.56. These revisions suggest higher expected losses or slower financial improvement. Annexon recently reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate. HC Wainwright revised estimates

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.